Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Bristol Myers Squibb (BMY)

NYSE Health Care Pharmaceuticals S&P 500
$62.14
-0.99 (-1.57%)
Close of Nov 06, 2026 · end-of-day data
Source: Bristol Myers Squibb's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 09, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$19.43B$20.78B$22.56B$26.14B$42.52B$46.38B$46.16B$45.01B$48.30B$48.19B
Cost of revenue$4.97B$6.01B$6.47B$8.08B$11.77B$9.94B$10.14B$10.69B$13.97B$13.94B
Gross profit$14.48B$14.68B$16.09B$18.07B$30.75B$36.45B$36.02B$34.31B$34.33B$34.26B
Research & development$5.01B$6.47B$6.33B$6.15B$10.05B$10.20B$9.51B$9.30B$11.16B$9.95B
Selling, general & admin$4.98B$4.75B$4.55B$4.87B$7.66B$7.69B$7.81B$7.77B$8.41B$7.27B
Interest expense$167.00M$196.00M$183.00M$656.00M$1.42B$1.33B$1.23B$1.17B$1.95B$1.89B
Pre-tax income$5.92B$5.13B$5.97B$4.97B-$6.87B$8.10B$7.71B$8.44B-$8.38B$9.33B
Income tax$1.41B$4.16B$1.02B$1.51B$2.12B$1.08B$1.37B$400.00M$554.00M$2.27B
Net income$4.46B$1.01B$4.92B$3.44B-$9.02B$6.99B$6.33B$8.03B-$8.95B$7.05B
EPS (basic)$2.67$0.61$3.01$2.02$-3.99$3.15$2.97$3.88$-4.41$3.47
EPS (diluted)$2.65$0.61$3.01$2.01$-3.99$3.12$2.95$3.86$-4.41$3.46
Diluted shares1.68B1.65B1.64B1.71B2.26B2.25B2.15B2.08B2.03B2.04B
Gross margin74.5%70.7%71.3%69.1%72.3%78.6%78.0%76.2%71.1%71.1%
Net margin22.9%4.8%21.8%13.2%-21.2%15.1%13.7%17.8%-18.5%14.6%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$4.24B$5.42B$6.91B$12.35B$14.55B$13.98B$9.12B$11.46B$10.35B$10.21B
Short-term investments$2.11B$1.39B$1.85B$3.05B$1.28B$2.99B$130.00M$816.00M$513.00M$464.00M
Receivables$3.77B$4.35B$4.64B$6.48B$7.22B$7.98B$8.15B$8.88B$9.01B$9.59B
Inventory$1.24B$1.17B$1.20B$4.29B$2.07B$2.10B$2.34B$2.66B$2.56B$2.69B
Total current assets$13.70B$14.85B$17.72B$29.35B$30.19B$33.26B$27.27B$31.77B$29.78B$29.39B
Goodwill$6.88B$6.86B$6.54B$22.49B$20.55B$20.50B$21.15B$21.17B$21.72B$21.75B
Total assets$33.71B$33.55B$34.99B$129.94B$118.48B$109.31B$96.82B$95.16B$92.60B$90.04B
Total current liabilities$8.84B$9.56B$10.65B$18.30B$19.08B$21.87B$21.89B$22.26B$23.77B$23.42B
Short-term debt$992.00M$987.00M$1.70B$3.35B$2.34B$4.95B$4.26B$3.12B$2.05B$2.26B
Long-term debt$5.72B$6.97B$5.65B$43.39B$48.34B$39.60B$35.06B$36.65B$47.60B$42.85B
Total debt$6.71B$7.96B$7.35B$46.73B$50.68B$44.55B$39.32B$39.77B$49.65B$45.11B
Total liabilities$17.36B$21.70B$20.86B$78.25B$80.60B$73.31B$65.70B$65.67B$76.22B$71.53B
Shareholders' equity$16.18B$11.74B$14.03B$51.60B$37.82B$35.95B$31.06B$29.43B$16.34B$18.47B

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$3.06B$5.28B$7.07B$8.21B$14.05B$16.21B$13.07B$13.86B$15.19B$14.16B
Capital expenditures$1.22B$1.05B$951.00M$836.00M$753.00M$973.00M$1.12B$1.21B$1.25B$1.31B
Free cash flow$1.84B$4.22B$6.12B$7.37B$13.30B$15.23B$11.95B$12.65B$13.94B$12.85B
Investing cash flow$1.48B-$66.00M-$2.00B-$9.91B-$10.86B-$538.00M-$1.06B-$2.29B-$21.35B-$4.13B
Financing cash flow-$2.65B-$4.08B-$3.54B$7.62B-$1.15B-$16.22B-$16.96B-$9.42B$5.13B-$10.35B
Dividends paid$2.55B$2.58B$2.61B$2.68B$4.08B$4.40B$4.63B$4.74B$4.86B$5.04B
Share buybacks$231.00M$2.47B$320.00M$7.30B$1.55B$6.29B$8.00B$5.16B$0$0
Stock-based compensation$205.00M$199.00M$221.00M$441.00M$779.00M$583.00M$457.00M$518.00M$507.00M$553.00M
Depreciation & amortization$382.00M$789.00M$637.00M$1.75B$10.38B$10.69B$10.28B$9.76B$9.60B$4.01B

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.